Methofill (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, which is essential for producing tetrahydrofolate, a cofactor for DNA and RNA synthesis. This inhibition reduces the proliferation of rapidly dividing cells, such as immune cells and cancer cells. Additionally, methotrexate increases extracellular adenosine, providing anti‑inflammatory effects that help control autoimmune disease activity.

The specific dose of Methofill is determined by the prescribing clinician based on the patient’s condition, weight, renal function, and treatment response. Dosage regimens can vary widely between rheumatologic and oncologic indications, and the prescriber will tailor the schedule to achieve optimal therapeutic benefit while minimizing risk.

Methofill is classified as contraindicated in pregnancy because it can cause fetal malformations and embryotoxicity. Women of childbearing potential should use effective contraception during treatment and for a period after discontinuation. Breastfeeding is not recommended, as methotrexate is excreted in milk and may harm the infant.

To request Methofill, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide and will ask for trade or institutional credentials. The sales team then provides pricing, availability, shipping details—including cold‑chain logistics if needed—and assists with import documentation.

Methofill (methotrexate) is a conventional synthetic DMARD, whereas many newer options are biologic agents such as TNF‑α inhibitors. Methotrexate is generally less expensive and administered via subcutaneous injection, but biologics may offer faster symptom control for some patients. Choice of therapy depends on disease severity, comorbidities, prior treatment response, and cost considerations.

Methofill should be stored at 2‑8 °C in a refrigerator. Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. If temporary storage at room temperature is unavoidable, limit exposure to less than 24 hours and return to refrigeration promptly.

Methofill is given as a subcutaneous injection, typically into the abdomen or thigh. The injection is performed by a healthcare professional or trained patient using a sterile needle and syringe. The injection site should be rotated to reduce local irritation, and proper aseptic technique must be followed to prevent infection.

The most serious risks include severe liver toxicity, pulmonary fibrosis, pancytopenia (dangerously low blood cell counts), renal impairment, and life‑threatening infections. Patients should be monitored regularly with liver function tests, complete blood counts, and renal assessments, and any signs of infection or respiratory symptoms should prompt immediate medical evaluation.

Methofill is contraindicated in patients with known hypersensitivity to methotrexate, severe hepatic disease, significant renal impairment, active infections, or existing bone‑marrow suppression. It should also be avoided in pregnant women and in individuals who cannot adhere to required monitoring protocols. Clinicians must evaluate each patient’s medical history before initiating therapy.